Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology
admin 7 hours agoSouth TvComments Off on Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology0 Views
PressBee – DAEJEON, South Korea, Jan. 20, 2026 /PRNewswire/ — Alteogen Inc. (KOSDAQ: 196170) announced today that the company has entered into an exclusive license a
